- SEKISUI Diagnostics completes £15.7 million cGMP capacity expansion at its UK facility.
- New capabilities target enzymes, proteins, antibody fragments, plasmids, and gene therapy drug manufacturing.
SEKISUI Diagnostics has announced the completion of a £15.7 million expansion of its cGMP-certified microbial manufacturing facility in the UK. This new capacity, pending licensing, will enable production of clinical-grade substances for enzyme, protein, antibody fragment, and plasmid-based therapies, including those targeting gene therapy.
The BioProduction division, part of SEKISUI Diagnostics, operates as a contract development and manufacturing organisation (CDMO) with expertise in microbial fermentation and protein purification. The upgraded site now includes Grade C fermentation and purification suites that support production scales of up to 1,000 litres, enhancing capabilities for both existing and prospective biopharma clients.
“This investment supports our growth in the biologics CDMO market,” said Robert Schruender, President & CEO of SEKISUI Diagnostics. He noted the facility aims to support increasing demand for manufacturing partners in the biologics sector.
Louise Digby, Vice President of Enzymes & BioProduction, highlighted that the expansion allows the company to broaden its customer reach, stating, “This cGMP expansion enables us to support a broader customer base and expand our offering to existing customers.”
Overview of outsourcing trends 
